Hope. Now within reach. Aiming to reach a billion patients worldwide with affordable, lifesaving medicines. Let's fight the COVID-19 outbreak DCGI gives NOD for Restricted Emergency Use of Itolizumab in Moderate to Severe COVID-19 Patients. Research saves lives. We are accelerating drug innovation and development for companies globally. Meeting unmet patient needs. Our novel biologics address unmet medical needs across the world. The 10-cent answer to Diabetes. At 10 cents a day our insulin
is a game changer in the developing world.
WHO WE ARE
Driven by purpose.
We are a global biopharmaceutical company with the belief that everyone, everywhere deserves access to affordable quality medicines.